Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/32474
Title: Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1
Authors: Felicio, Andre C. [UNIFESP]
Godeiro-Junior, Clecio [UNIFESP]
Shih, Ming C. [UNIFESP]
Borges, Vanderci [UNIFESP]
Silva, Sonia M. A. [UNIFESP]
Aguiar, Patricia de Carvalho [UNIFESP]
Hoexter, Marcelo Q. [UNIFESP]
Barsottini, Orlando G. P.
Andrade, Luiz A. F.
Bressan, Rodrigo A. [UNIFESP]
Ferraz, Henrique B. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
Keywords: Clinically Unclear Parkinsonian Syndromes
Parkinson's Disease
SPECT
TRODAT-1
Dopamine transporter
Issue Date: 15-Apr-2010
Publisher: Elsevier B.V.
Citation: Journal of the Neurological Sciences. Amsterdam: Elsevier B.V., v. 291, n. 1-2, p. 64-68, 2010.
Abstract: Despite its relatively high prevalence Parkinson's Disease (PD) is still misdiagnosed in approximately 25% of cases. in this study our aim was to evaluate patients with Clinically Unclear Parkinsonian Syndromes (CUPS) submitted to brain SPECT imaging using the technetium-99m labeled Dopamine Transporter (DAT) tracer TRODAT-1. We recruited 15 subjects with CUPS and matched them with 13 patients with probable PD and 13 healthy control subjects (HCS). A SPECT with TRODAT-1 was performed at the baseline evaluation and patients from the CUPS were followed-up for 2-years to ensure or not PD diagnosis (gold-standard). the mean +/- SD results from Right and Left striatum Binding Potential (BP) were, respectively, 1.08 +/- 0.20 and 1.04 +/- 0.16 in the HCS group, 0.47 +/- 0.16 and 0.53 +/- 0.17 in the PD group, and 0.68 +/- 0.11 and 0.84 +/- 0.17 in the CUPS group. the rate of disagreement between baseline SPECT in the CUPS group as compared to the gold standard diagnosis (clinical diagnosis of PD on follow-up) was of 20%. the sensitivity of the SPECT with TRODAT-1 was 100%, while specificity was 70%. in conclusion, our data provided further information about the role of the technetium-99m labeled tracer TRODAT-1 as a biomarker of DAT reduction that can also be used in the diagnosis of patients with CUPS. (C) 2010 Elsevier By. All rights reserved.
URI: http://repositorio.unifesp.br/handle/11600/32474
ISSN: 0022-510X
Other Identifiers: http://dx.doi.org/10.1016/j.jns.2009.12.024
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.